Portfolio company
Atreca
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biotechnology firm developed antibody-based immunotherapies for cancer and malaria, targeting healthcare providers and patients, before initiating liquidation and selling its assets in 2024.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Redona Therapeutics
This biotechnology company develops small molecule therapies targeting nucleic acid regulators to treat cancer and autoimmune diseases for healthcare providers and pharmaceutical partners.
Alphina Therapeutics
This biotechnology company develops antibody-drug conjugates with novel payloads to treat solid tumours for healthcare providers and cancer patients.
Mersana Therapeutics
This company develops antibody-drug conjugates to treat various cancers for healthcare providers and patients within the oncology sector.
Avidicure
This biotechnology company develops multifunctional antibody therapies for cancer patients to activate immune responses while reducing toxicity.
C4 Therapeutics
This biopharmaceutical company develops small-molecule medicines that degrade disease-causing proteins to treat cancer and other difficult diseases for patients and healthcare providers.
Hookipa Pharma
This biopharmaceutical company develops arenavirus-based immunotherapies to treat infectious diseases and cancers for patients and healthcare providers.
Lead Biologics
The company develops antibody-based immunotherapies for cancer and autoimmune diseases, targeting pharmaceutical firms and research institutions for early-stage development and collaboration.
Eradivir
This biotechnology company develops small molecule immunotherapies that target viral infections and cancers for healthcare providers and patients.
